PMV Pharmaceuticals Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

PMVP$1.22-2.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

Condensed Consolidated Statements of Opera tions and Comprehensive Loss

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Operating expenses:
Research and development	$16,947	$13,586	$44,760	$42,503
General and administrative	4,941	6,042	15,520	18,727
Total operating expenses	21,888	19,628	60,280	61,230
Loss from operations	(21,888)	(19,628)	(60,280)	(61,230)
Other income (expense):
Interest income, net	2,615	2,984	8,368	8,005
Other income, net	121	4	103	24
Total other income	2,736	2,988	8,471	8,029
Loss before provision for income taxes	(19,152)	(16,640)	(51,809)	(53,201)
Provision (benefit) for income taxes	74	—	(16,100)	3
Net loss	(19,226)	(16,640)	(35,709)	(53,204)
Unrealized gain (loss) on available for sale investments, net of tax	591	(27)	211	90
Foreign currency translation gain (loss)	4	—	(25)	—
Total other comprehensive income (loss)	595	(27)	186	90
Total comprehensive loss	$(18,631)	$(16,667)	$(35,523)	$(53,114)
Net loss per share -- basic and diluted	$(0.37)	$(0.34)	$(0.69)	$(1.13)
Weighted-average common shares outstanding	51,574,027	49,047,296	51,499,818	46,889,921

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.